PMID- 33134479
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 2352-9067 (Print)
IS  - 2352-9067 (Electronic)
IS  - 2352-9067 (Linking)
VI  - 31
DP  - 2020 Dec
TI  - Effects of sacubitril valsartan on clinical and echocardiographic parameters of 
      outpatients with heart failure and reduced ejection fraction.
PG  - 100656
LID - 10.1016/j.ijcha.2020.100656 [doi]
LID - 100656
AB  - AIM: Sacubitril valsartan (SV) has revolutionized disease history in patients 
      with heart failure and reduced ejection fraction (HFrEF). Our study assessed SV 
      impact on clinical and echocardiographic parameters in HFrEF outpatients 
      previously treated with optimized therapy. METHODS: Forty-nine HFrEF outpatients 
      were retrospectively included in the study. We collected data from transthoracic 
      echocardiography and clinical assessment at baseline and after 3 +/- 1 and 
      12 +/- 1 months of treatment with SV. Results were also stratified by sex to 
      analyse possible sex-based differences in reverse remodelling response to SV. 
      RESULTS: After 3 months of treatment we observed a significative improvement of 
      both systolic and diastolic function with a reduction of left ventricular mass 
      and relative wall thickness (RWT). At 12 months we observed a further improvement 
      of all previous parameters, plus systolic pulmonary artery pressure (PAP) and 
      left atrial (LA) diameter. In women, most of the echocardiographic parameters 
      improved after SV initiation, but did not reach the statistical significance, 
      except for left ventricular ejection fraction (LVEF), PAP and LA diameter. As for 
      clinical parameters, SV improved New York Heart Association (NYHA) Class, 
      systolic blood pressure and loop diuretic dosage with a mild but significative 
      increase in serum creatinine and potassium. CONCLUSION: Our study showed 
      significative reverse remodelling properties of SV with an improvement of LV 
      volumes, mass and systo-diastolic function. NYHA Class, systolic blood pressure 
      and loop diuretic dosage also improved with only mild increase in serum 
      creatinine and potassium. Women showed a lesser extent of reverse remodelling 
      compared with men.
CI  - (c) 2020 The Author(s).
FAU - Landolfo, Matteo
AU  - Landolfo M
AD  - Department of Medical and Surgical Sciences, University of Bologna, Bologna, 
      Italy.
FAU - Piani, Federica
AU  - Piani F
AD  - Department of Medical and Surgical Sciences, University of Bologna, Bologna, 
      Italy.
FAU - Esposti, Daniela Degli
AU  - Esposti DD
AD  - Cardio-Thoraco-Vascular Department, Azienda Ospedaliero Universitaria S.Orsola 
      Malpighi, Bologna, Italy.
FAU - Cosentino, Eugenio
AU  - Cosentino E
AD  - Cardio-Thoraco-Vascular Department, Azienda Ospedaliero Universitaria S.Orsola 
      Malpighi, Bologna, Italy.
FAU - Bacchelli, Stefano
AU  - Bacchelli S
AD  - Cardio-Thoraco-Vascular Department, Azienda Ospedaliero Universitaria S.Orsola 
      Malpighi, Bologna, Italy.
FAU - Dormi, Ada
AU  - Dormi A
AD  - Department of Medical and Surgical Sciences, University of Bologna, Bologna, 
      Italy.
FAU - Borghi, Claudio
AU  - Borghi C
AD  - Department of Medical and Surgical Sciences, University of Bologna, Bologna, 
      Italy.
LA  - eng
PT  - Journal Article
DEP - 20201022
PL  - Ireland
TA  - Int J Cardiol Heart Vasc
JT  - International journal of cardiology. Heart & vasculature
JID - 101649525
PMC - PMC7586107
OTO - NOTNLM
OT  - Echocardiography
OT  - Entresto
OT  - Heart failure
OT  - Reverse remodelling
OT  - Sacubitril valsartan
OT  - Sex differences
COIS- The authors report no relationships that could be construed as a conflict of 
      interest.
EDAT- 2020/11/03 06:00
MHDA- 2020/11/03 06:01
PMCR- 2020/10/22
CRDT- 2020/11/02 06:21
PHST- 2020/08/11 00:00 [received]
PHST- 2020/09/23 00:00 [revised]
PHST- 2020/09/29 00:00 [accepted]
PHST- 2020/11/02 06:21 [entrez]
PHST- 2020/11/03 06:00 [pubmed]
PHST- 2020/11/03 06:01 [medline]
PHST- 2020/10/22 00:00 [pmc-release]
AID - S2352-9067(20)30354-7 [pii]
AID - 100656 [pii]
AID - 10.1016/j.ijcha.2020.100656 [doi]
PST - epublish
SO  - Int J Cardiol Heart Vasc. 2020 Oct 22;31:100656. doi: 
      10.1016/j.ijcha.2020.100656. eCollection 2020 Dec.